Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 67 Breast Neoplasms, Male 4 Neoplasm Metastasis 3 Neoplasms 2 Advanced Breast Cancer 2 Unilateral Breast Neoplasms 1 Sleep Wake Disorders 1 Recurrence 1 Ovarian Neoplasms 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1 First Line Metastatic Breast Cancer 1 Fatigue 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Paclitaxel 79 Carboplatin 64 Bevacizumab 33 liposomal doxorubicin 29 Topotecan 28 Gemcitabine 25 Cisplatin 19 olaparib 18 Drug Therapy 12 Doxorubicin 12 Taxes 11 niraparib 9 Docetaxel 6 CP protocol 6 Trabectedin 5 Hyperthermic Intraperitoneal Chemotherapy 5 Etoposide 5 Cyclophosphamide 5 1-dodecylpyridoxal 5 rucaparib 4 pembrolizumab 4 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Disulfides 4 Dexamethasone 4 Chemotherapy, Adjuvant 4 trebananib 3 fluzoparib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × exemestane × Clear all

NCT04460807 2024-02-12

EXPERT

Ente Ospedaliero Ospedali Galliera

Phase 3 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡